

Ho-Young Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1224178/publications.pdf>

Version: 2024-02-01

129
papers

7,082
citations

47006

47
h-index

64796

79
g-index

132
all docs

132
docs citations

132
times ranked

8712
citing authors

#	ARTICLE	IF	CITATIONS
1	Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib. <i>Cancer Research</i> , 2006, 66, 10100-10111.	0.9	313
2	Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. <i>Clinical Cancer Research</i> , 2002, 8, 1178-84.	7.0	312
3	Direct Functional Interactions between Insulin-like Growth Factor-binding Protein-3 and Retinoid X Receptor-1± Regulate Transcriptional Signaling and Apoptosis. <i>Journal of Biological Chemistry</i> , 2000, 275, 33607-33613.	3.4	287
4	Effects of Deguelin on the Phosphatidylinositol 3-Kinase/Akt Pathway and Apoptosis in Premalignant Human Bronchial Epithelial Cells. <i>Journal of the National Cancer Institute</i> , 2003, 95, 291-302.	6.3	248
5	Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non-“small Cell Lung Cancer Cells to Treatment with Gefitinib. <i>Clinical Cancer Research</i> , 2007, 13, 2795-2803.	7.0	248
6	Designing a broad-spectrum integrative approach for cancer prevention and treatment. <i>Seminars in Cancer Biology</i> , 2015, 35, S276-S304.	9.6	220
7	Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice. <i>Gastroenterology</i> , 2017, 153, 277-291.e19.	1.3	193
8	Anti-angiogenic activity of triterpene acids. <i>Cancer Letters</i> , 1995, 94, 213-218.	7.2	157
9	Chemopreventive Effects of Deguelin, a Novel Akt Inhibitor, on Tobacco-Induced Lung Tumorigenesis. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1695-1699.	6.3	145
10	Structural Basis for Depletion of Heat Shock Protein 90 Client Proteins by Deguelin. <i>Journal of the National Cancer Institute</i> , 2007, 99, 949-961.	6.3	141
11	Glucocorticoid-induced tumor necrosis factor receptor-“related protein co-stimulation facilitates tumor regression by inducing IL-9-“producing helper T cells. <i>Nature Medicine</i> , 2015, 21, 1010-1017.	30.7	131
12	Targeting Heat Shock Protein 90 Overrides the Resistance of Lung Cancer Cells by Blocking Radiation-Induced Stabilization of Hypoxia-Inducible Factor-1±. <i>Cancer Research</i> , 2009, 69, 1624-1632.	0.9	124
13	Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. <i>Cancer Research</i> , 2002, 62, 3530-7.	0.9	124
14	Targeted therapies in squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2009, 115, 922-935.	4.1	122
15	Interleukin-1±-mediated Suppression of RXR:RAR Transactivation of the Ntcp Promoter Is JNK-dependent. <i>Journal of Biological Chemistry</i> , 2002, 277, 31416-31422.	3.4	113
16	SPON2 Promotes M1-like Macrophage Recruitment and Inhibits Hepatocellular Carcinoma Metastasis by Distinct Integrin-“Rho GTPase-“Hippo Pathways. <i>Cancer Research</i> , 2018, 78, 2305-2317.	0.9	112
17	Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2002, 8, 3669-75.	7.0	111
18	Hypoxia-inducible Factor 1± and Antiangiogenic Activity of Farnesyltransferase Inhibitor SCH66336 in Human Aerodigestive Tract Cancer. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1272-1286.	6.3	101

#	ARTICLE	IF	CITATIONS
19	Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. <i>Seminars in Cancer Biology</i> , 2015, 35, S55-S77.	9.6	95
20	Design, Synthesis, and Biological Evaluation of Novel Deguelin-Based Heat Shock Protein 90 (HSP90) Inhibitors Targeting Proliferation and Angiogenesis. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10863-10884.	6.4	92
21	All- <i>trans</i> -Retinoic Acid Inhibits Jun N-Terminal Kinase by Increasing Dual-Specificity Phosphatase Activity. <i>Molecular and Cellular Biology</i> , 1999, 19, 1973-1980.	2.3	91
22	All- <i>trans</i> -retinoic Acid Increases Transforming Growth Factor- β 2 and Insulin-like Growth Factor Binding Protein-3 Expression through a Retinoic Acid Receptor- α -dependent Signaling Pathway. <i>Journal of Biological Chemistry</i> , 1997, 272, 13711-13716.	3.4	88
23	Resistance to epidermal growth factor receptor-targeted therapy. <i>Drug Resistance Updates</i> , 2005, 8, 298-310.	14.4	84
24	Implication of AMP-Activated Protein Kinase and Akt-Regulated Survivin in Lung Cancer Chemopreventive Activities of Deguelin. <i>Cancer Research</i> , 2007, 67, 11630-11639.	0.9	83
25	Stress Pathway Activation Induces Phosphorylation of Retinoid X Receptor. <i>Journal of Biological Chemistry</i> , 2000, 275, 32193-32199.	3.4	82
26	Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. <i>Annals of Neurology</i> , 2003, 53, 109-117.	5.3	81
27	Induction of differentiation in the cultured F9 teratocarcinoma stem cells by triterpene acids. <i>Journal of Cancer Research and Clinical Oncology</i> , 1994, 120, 513-518.	2.5	80
28	Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2002, 8, 3796-802.	7.0	78
29	Effects of Insulin-like Growth Factor Binding Protein-3 and Farnesyltransferase Inhibitor SCH66336 on Akt Expression and Apoptosis in Non-Small-Cell Lung Cancer Cells. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1536-1548.	6.3	72
30	Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 α . <i>International Journal of Cancer</i> , 2008, 122, 5-14.	5.1	71
31	Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. <i>Oncogene</i> , 2000, 19, 4432-4436.	5.9	69
32	Down-Regulation of Inhibitor of Apoptosis Proteins by Deguelin Selectively Induces Apoptosis in Breast Cancer Cells. <i>Molecular Pharmacology</i> , 2007, 71, 101-111.	2.3	65
33	Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. <i>Oncogene</i> , 2004, 23, 6569-6580.	5.9	63
34	Mechanisms of resistance to chemotherapy in non-small cell lung cancer. <i>Archives of Pharmacal Research</i> , 2021, 44, 146-164.	6.3	62
35	Molecular mechanisms of deguelin-induced apoptosis in transformed human bronchial epithelial cells. <i>Biochemical Pharmacology</i> , 2004, 68, 1119-1124.	4.4	61
36	Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events. <i>Blood</i> , 2011, 118, 2622-2631.	1.4	61

#	ARTICLE	IF	CITATIONS
37	Association of a functional tandem repeats in the downstream of human telomerase gene and lung cancer. <i>Oncogene</i> , 2003, 22, 7123-7129.	5.9	60
38	Deguelin-Induced Inhibition of Cyclooxygenase-2 Expression in Human Bronchial Epithelial Cells. <i>Clinical Cancer Research</i> , 2004, 10, 1074-1079.	7.0	60
39	Elevated Epithelial Insulin-like Growth Factor Expression Is a Risk Factor for Lung Cancer Development. <i>Cancer Research</i> , 2009, 69, 7439-7448.	0.9	60
40	Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors. <i>FEBS Journal</i> , 2009, 276, 4653-4664.	4.7	58
41	Oncogene-Driven Metabolic Alterations in Cancer. <i>Biomolecules and Therapeutics</i> , 2018, 26, 45-56.	2.4	58
42	Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. <i>Cancer</i> , 2012, 118, 2454-2465.	4.1	57
43	Anoctamin 1 (TMEM16A) is essential for testosterone-induced prostate hyperplasia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9722-9727.	7.1	53
44	Response of Non-Small Cell Lung Cancer Cells to the Inhibitors of Phosphatidylinositol 3-Kinase/Akt- and MAPK Kinase 4/c-Jun NH2-Terminal Kinase Pathways: An Effective Therapeutic Strategy for Lung Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 6065-6074.	7.0	52
45	Insulin-like Growth Factor-I Receptor Signaling Pathway Induces Resistance to the Apoptotic Activities of SCH66336 (Lonafarnib) through Akt/Mammalian Target of Rapamycin-Mediated Increases in Survivin Expression. <i>Clinical Cancer Research</i> , 2008, 14, 1581-1589.	7.0	51
46	A Novel Derivative of the Natural Agent Deguelin for Cancer Chemoprevention and Therapy. <i>Cancer Prevention Research</i> , 2008, 1, 577-587.	1.5	51
47	Evidence That Phosphatidylinositol 3-Kinase- and Mitogen-activated Protein Kinase Kinase-4/c-Jun NH2-terminal Kinase-dependent Pathways Cooperate to Maintain Lung Cancer Cell Survival. <i>Journal of Biological Chemistry</i> , 2003, 278, 23630-23638.	3.4	48
48	Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 653-661.	7.0	48
49	All-trans-Retinoic Acid Inhibits Jun N-terminal Kinase-dependent Signaling Pathways. <i>Journal of Biological Chemistry</i> , 1998, 273, 7066-7071.	3.4	46
50	Acquired resistance to 5-fluorouracil via HSP90/Src-mediated increase in thymidylate synthase expression in colon cancer. <i>Oncotarget</i> , 2015, 6, 32622-32633.	1.8	45
51	The natural compound gracillin exerts potent antitumor activity by targeting mitochondrial complex II. <i>Cell Death and Disease</i> , 2019, 10, 810.	6.3	45
52	Lonafarnib in cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 709-719.	4.1	44
53	Akt/mTOR Counteract the Antitumor Activities of Cixutumumab, an Anti-Insulin-like Growth Factor I Receptor Monoclonal Antibody. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2437-2448.	4.1	44
54	Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2685-2695.	4.1	43

#	ARTICLE	IF	CITATIONS
55	Survivin expression in normal human bronchial epithelial cells: an early and critical step in tumorigenesis induced by tobacco exposure. <i>Carcinogenesis</i> , 2008, 29, 1614-1622.	2.8	43
56	Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. <i>Cancer Research</i> , 2003, 63, 4796-800.	0.9	42
57	Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β 3-Src Pathway. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1558-1570.	6.3	41
58	Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells. <i>Cancer Research</i> , 2016, 76, 6607-6619.	0.9	41
59	Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity. <i>Cancer Research</i> , 2016, 76, 686-699.	0.9	41
60	p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells. <i>Oncotarget</i> , 2016, 7, 8184-8199.	1.8	41
61	Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXR α phosphorylation. <i>Journal of Clinical Investigation</i> , 2005, 115, 2924-2933.	8.2	40
62	Epidermal growth factor receptor and <i>K-Ras</i> mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. <i>Cancer</i> , 2012, 118, 3993-4003.	4.1	39
63	Panaxynol, a natural Hsp90 inhibitor, effectively targets both lung cancer stem and non-stem cells. <i>Cancer Letters</i> , 2018, 412, 297-307.	7.2	39
64	Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90. <i>Molecular Pharmacology</i> , 2015, 88, 245-255.	2.3	38
65	The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. <i>Cancer Letters</i> , 2006, 239, 136-143.	7.2	37
66	Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma. <i>Cancer Science</i> , 2012, 103, 1259-1266.	3.9	36
67	Hypoxia-mediated retinal neovascularization and vascular leakage in diabetic retina is suppressed by HIF-1 α destabilization by SH-1242 and SH-1280, novel hsp90 inhibitors. <i>Journal of Molecular Medicine</i> , 2014, 92, 1083-1092.	3.9	36
68	Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer. <i>Molecular Cancer</i> , 2015, 14, 113.	19.2	36
69	Anti-angiogenic activity of ursodeoxycholic acid and its derivatives. <i>Cancer Letters</i> , 1997, 113, 117-122.	7.2	35
70	STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody. <i>Nature Communications</i> , 2015, 6, 8499.	12.8	34
71	Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. <i>Journal of Cellular Physiology</i> , 2008, 216, 698-707.	4.1	33
72	Liposomal Encapsulation of Deguelin: Evidence for Enhanced Antitumor Activity in Tobacco Carcinogen-Induced and Oncogenic K-ras-Induced Lung Tumorigenesis. <i>Cancer Prevention Research</i> , 2009, 2, 361-369.	1.5	33

#	ARTICLE	IF	CITATIONS
73	Insulin-Like Growth Factor Binding Protein-6 Inhibits the Growth of Human Bronchial Epithelial Cells and Increases in Abundance with All- <i>trans</i> -Retinoic Acid Treatment. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2000, 23, 297-303.	2.9	32
74	Antiangiogenic Effect of Deguelin on Choroidal Neovascularization. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 324, 643-647.	2.5	31
75	A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer. <i>Cancer Letters</i> , 2013, 332, 102-109.	7.2	31
76	The tobacco-specific carcinogen-operated calcium channel promotes lung tumorigenesis via IGF2 exocytosis in lung epithelial cells. <i>Nature Communications</i> , 2016, 7, 12961.	12.8	31
77	Involvement of glucocorticoid receptor in the induction of differentiation by ginsenosides in F9 teratocarcinoma cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1998, 67, 105-111.	2.5	29
78	Evodiamine inhibits both stem cell and non-stem-cell populations in human cancer cells by targeting heat shock protein 70. <i>Theranostics</i> , 2021, 11, 2932-2952.	10.0	29
79	Ring-truncated deguelin derivatives as potent Hypoxia Inducible Factor-1 \pm (HIF-1 \pm) inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2015, 104, 157-164.	5.5	24
80	Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 6082-6093.	3.0	24
81	Essential Role of DNA Methyltransferase 1 α -mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 1299-1311.	7.0	24
82	Deguelin inhibits vasculogenic function of endothelial progenitor cells in tumor progression and metastasis via suppression of focal adhesion. <i>Oncotarget</i> , 2015, 6, 16588-16600.	1.8	24
83	Dual Targeting of the Insulin-Like Growth Factor and Collateral Pathways in Cancer: Combating Drug Resistance. <i>Cancers</i> , 2011, 3, 3029-3054.	3.7	23
84	Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer. <i>Scientific Reports</i> , 2018, 8, 13924.	3.3	23
85	RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	23
86	A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt- β -catenin signaling-mediated drug resistance and adverse effects. <i>Theranostics</i> , 2022, 12, 105-125.	10.0	23
87	Involvement of Mitochondrial and Akt Signaling Pathways in Augmented Apoptosis Induced by a Combination of Low Doses of Celecoxib and N-(4-Hydroxyphenyl) Retinamide in Premalignant Human Bronchial Epithelial Cells. <i>Cancer Research</i> , 2006, 66, 9762-9770.	0.9	22
88	Prognostic Implications of Tumoral Expression of Insulin Like Growth Factors 1 and 2 in Patients With Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 213-221.	2.6	22
89	Potent Anticancer Effect of the Natural Steroidal Saponin Gracillin Is Produced by Inhibiting Glycolysis and Oxidative Phosphorylation-Mediated Bioenergetics. <i>Cancers</i> , 2020, 12, 913.	3.7	22
90	Suppression of c-Fos gene transcription with malignant transformation of human bronchial epithelial cells. <i>Oncogene</i> , 1998, 16, 3039-3046.	5.9	21

#	ARTICLE	IF	CITATIONS
91	A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer. <i>Scientific Reports</i> , 2019, 9, 648.	3.3	21
92	Differential Impacts of Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) in Epithelial IGF-Induced Lung Cancer Development. <i>Endocrinology</i> , 2011, 152, 2164-2173.	2.8	20
93	The Interplay between Slow-Cycling, Chemoresistant Cancer Cells and Fibroblasts Creates a Proinflammatory Niche for Tumor Progression. <i>Cancer Research</i> , 2020, 80, 2257-2272.	0.9	20
94	Ninjurin1 suppresses metastatic property of lung cancer cells through inhibition of interleukin 6 signaling pathway. <i>International Journal of Cancer</i> , 2016, 139, 383-395.	5.1	19
95	Inhibition of oncogenic K-ras signaling by aerosolized gene delivery in a mouse model of human lung cancer. <i>Clinical Cancer Research</i> , 2002, 8, 2970-5.	7.0	19
96	Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice. <i>PLoS ONE</i> , 2017, 12, e0173247.	2.5	18
97	Ninjurin1 inhibits colitis-mediated colon cancer development and growth by suppression of macrophage infiltration through repression of FAK signaling. <i>Oncotarget</i> , 2016, 7, 29592-29604.	1.8	18
98	Smoking-associated lung cancer prevention by blockade of the beta-adrenergic receptor-mediated insulin-like growth factor receptor activation. <i>Oncotarget</i> , 2016, 7, 70936-70947.	1.8	17
99	The novel IGF-IR/Akt-dependent anticancer activities of glucosamine. <i>BMC Cancer</i> , 2014, 14, 31.	2.6	16
100	Downregulation of malic enzyme 1 and 2: Sensitizing head and neck squamous cell carcinoma cells to therapy-induced senescence. <i>Head and Neck</i> , 2016, 38, E934-40.	2.0	16
101	Small molecule activator of Nm23/NDPK as an inhibitor of metastasis. <i>Scientific Reports</i> , 2018, 8, 10909.	3.3	16
102	Insulin-like growth factor binding protein-3 inhibits cell adhesion via suppression of integrin β 4 expression. <i>Oncotarget</i> , 2015, 6, 15150-15163.	1.8	16
103	Bidirectional signaling between TM4SF5 and IGF1R promotes resistance to EGFR kinase inhibitors. <i>Lung Cancer</i> , 2015, 90, 22-31.	2.0	15
104	The ATF6-EGF Pathway Mediates the Awakening of Slow-Cycling Chemoresistant Cells and Tumor Recurrence by Stimulating Tumor Angiogenesis. <i>Cancers</i> , 2020, 12, 1772.	3.7	15
105	Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity. <i>Molecular Cancer</i> , 2018, 17, 50.	19.2	13
106	Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 16746-16756.	1.8	13
107	Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase. <i>British Journal of Cancer</i> , 2022, 127, 661-674.	6.4	12
108	A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer. <i>International Journal of Cancer</i> , 2012, 131, 537-547.	5.1	11

#	ARTICLE	IF	CITATIONS
109	Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors. <i>Cancer Letters</i> , 2015, 361, 197-206.	7.2	11
110	Development of the phenylpyrazolo[3,4- <i>d</i>]pyrimidine-based, insulin-like growth factor receptor/Src/AXL-targeting small molecule kinase inhibitor. <i>Theranostics</i> , 2021, 11, 1918-1936.	10.0	11
111	Effects of 9-cis-Retinoic Acid on the Insulin-Like Growth Factor Axis in Former Smokers. <i>Journal of Clinical Oncology</i> , 2005, 23, 4439-4449.	1.6	10
112	Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro. <i>Molecular Cancer</i> , 2009, 8, 99.	19.2	10
113	Transcriptional and posttranslational regulation of insulin-like growth factor binding protein-3 by Akt3. <i>Carcinogenesis</i> , 2014, 35, 2232-2243.	2.8	10
114	Insulin-Like Growth Factor Binding Protein-3 Exerts Its Anti-Metastatic Effect in Aerodigestive Tract Cancers by Disrupting the Protein Stability of Vimentin. <i>Cancers</i> , 2021, 13, 1041.	3.7	10
115	Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation. <i>International Journal of Cancer</i> , 2012, 131, 2253-2263.	5.1	8
116	Papuanine Inhibits Viability of Non-small Cell Lung Cancer Cells by Inducing Mitochondrial Dysfunction. <i>Anticancer Research</i> , 2020, 40, 323-333.	1.1	8
117	How Can We Treat Cancer Disease Not Cancer Cells?. <i>Cancer Research and Treatment</i> , 2017, 49, 1-9.	3.0	7
118	Erybraedin A is a potential Src inhibitor that blocks the adhesion and viability of non-small-cell lung cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2018, 502, 145-151.	2.1	7
119	LJ-529, a partial peroxisome proliferator-activated receptor gamma (PPAR γ) agonist and adenosine A3 receptor agonist, ameliorates elastase-induced pulmonary emphysema in mice. <i>Archives of Pharmacal Research</i> , 2020, 43, 540-552.	6.3	7
120	Small molecule-induced simultaneous destabilization of β -catenin and RAS is an effective molecular strategy to suppress stemness of colorectal cancer cells. <i>Cell Communication and Signaling</i> , 2020, 18, 38.	6.5	7
121	Reduced expression of PLC- β during the differentiation of mouse F9 teratocarcinoma cells. <i>Cancer Letters</i> , 1993, 68, 237-242.	7.2	6
122	Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents. <i>Oncotarget</i> , 2015, 6, 40598-40610.	1.8	6
123	Ninjurin1 drives lung tumor formation and progression by potentiating Wnt/ β -Catenin signaling through Frizzled2-LRP6 assembly. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 133.	8.6	6
124	9-cis-Retinoic Acid Treatment Increases Serum Concentrations of α -Tocopherol in Former Smokers. <i>Clinical Cancer Research</i> , 2005, 11, 2305-2311.	7.0	5
125	A preclinical murine model for the detection of circulating human tumor cells. <i>Anticancer Research</i> , 2013, 33, 4751-6.	1.1	4
126	LJ-2698, an Adenosine A3 Receptor Antagonist, Alleviates Elastase-Induced Pulmonary Emphysema in Mice. <i>Biomolecules and Therapeutics</i> , 2020, 28, 250-258.	2.4	2

#	ARTICLE	IF	CITATIONS
127	Preventive effects of cristacarpin on experimentally induced uveitis by targeting NF- κ B. <i>Biomedicine and Pharmacotherapy</i> , 2022, 145, 112474.	5.6	1
128	Ethanol Extract of <i>Sargassum siliquastrum</i> Inhibits Lipopolysaccharide-Induced Nitric Oxide Generation by Downregulating the Nuclear Factor-Kappa B Signaling Pathway. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-11.	1.2	1
129	Editor's Note: Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 4861-4861.	7.0	0